modelG03FA12
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | MedroxyprogesteroneAndEstrogen | |
| ATC code: | G03FA12 | route: | oral |
| compartments: | 1 | |
| dosage: | 2.5 | mg |
| volume of distribution: | 20 | L |
| clearance: | 3 | L/h |
| other parameters in model implementation | ||
Medroxyprogesterone and estrogen is a combination hormonal therapy primarily indicated for hormone replacement therapy in postmenopausal women to alleviate menopausal symptoms and to reduce the risk of osteoporosis. Medroxyprogesterone is a synthetic progestin, and estrogen (usually as conjugated estrogens or estradiol) is a natural female sex hormone. This combination is approved and used currently for hormone replacement therapy.
Pharmacokinetics
Pharmacokinetic parameters estimated for a typical adult woman following oral administration of standard clinical doses. No published population pharmacokinetic model or clinical PK study directly reporting all parameters for this combination. Estimates are based on published PK for single agents.
References
Garza-Flores, J, et al., & Perez-Palacios, G (1991). Long-acting hormonal contraceptives for women. The Journal of steroid biochemistry and molecular biology 40(4-6) 697–704. DOI:10.1016/0960-0760(91)90293-e PUBMED:https://pubmed.ncbi.nlm.nih.gov/1958567
Zhou, XF, et al., & Sang, GW (1998). Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. Contraception 57(6) 405–411. DOI:10.1016/s0010-7824(98)00048-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9693401
Cromie, MA, et al., & Wajszczuk, CP (2000). Comparative effects of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic) on lipid profiles. Investigators from the Lunelle Study Group. Contraception 61(1) 51–59. DOI:10.1016/s0010-7824(99)00114-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10745070
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)